Melony Jaggers
Primary Care · McDaniels, KYNPI 1093339772
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 35.1% of the total.
Across 106 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$621
- Bayer$208
- Biohaven Pharmaceutical Holding Company Ltd.$180
- Novo Nordisk$148
- Lundbeck LLC$103
- Amgen$68
- plus $442 from 11 others
What the payments were for
- Food & beverage$1,72097%
- Education$503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $621 |
| Bayer | 13 | $208 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $180 |
| Novo Nordisk | 10 | $148 |
| Lundbeck LLC | 6 | $103 |
| Amgen | 5 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Alkermes, Inc. | 3 | $49 |
| GSK | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Lilly USA, LLC | 3 | $42 |
| Pfizer | 2 | $34 |
| Novartis | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$111
How this compares
$1,770 in reported general payments places this provider in the 80th percentile of 80 primary care providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $66,255 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $40,673 |
| EliquisApixaban | 26 | $29,820 |
| RexultiBrexpiprazole | 14 | $20,540 |
| FarxigaDapagliflozin Propanediol | 21 | $19,628 |
| EntrestoSacubitril/Valsartan | 18 | $17,857 |
| VraylarCariprazine Hcl | 12 | $17,058 |
| LinzessLinaclotide | 26 | $15,008 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,135 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,168 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,716 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,075 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $1,836 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,453 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $1,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $148 | $66,25560 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $45 | $51,52570 claims |
| AbbVieVraylar, Linzess | $621 | $32,06638 claims |
| PfizerEliquis | $34 | $29,82026 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $53 | $20,54014 claims |
| AstraZenecaFarxiga | $14 | $19,62821 claims |
| NovartisEntresto | $34 | $17,85718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 80 primary care providers in Kentucky.
Other primary care in McDaniels
- Jessica GoettlLouisville$59K
- Angela ClarkBowling Green$10K
- Tara CoyleShelbyville$7K
- Heather AdamsLexington$7K
- Bridget McKinleyElizabethtown$6K
- Tracy DarlingtonCrestview Hills$6K
- Reagen LoughranLondon$6K
- Jeryl PittmanRichmond$6K
- Samantha FraleyPrestonsburg$3K
- Pamela PhelpsMorgantown$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.